PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...
A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...
The SANRECO study investigates divesiran for polycythemia vera, focusing on regulating iron metabolism to control red blood cell production. Current PV treatments include therapeutic phlebotomy, ...
Protagonist Therapeutics, Inc. (PTGX) has been making great progress to advance the use of its drug rusfertide for the treatment of patients with polycythemia vera in the ongoing phase 3 study. Matter ...
The Phase 1 study of PRT12396 is an open-label, multi-center, safety and efficacy study in patients with high-risk polycythemia vera (PV) and intermediate and high-risk myelofibrosis (MF). The primary ...
Breakthrough designation for rusfertide was supported by positive 32-week data from the Phase 3 VERIFY study, which was presented as a late breaking abstract highlighting its practice-changing ...
Dr Gerds explores the pros and cons of the present treatment approach for PV. Aaron Gerds, MD, MS: To date for the MPNs [myeloproliferative neoplasms] and polycythemia vera [PV], the only treatment ...
While treatment options may be fairly straightforward for high-risk patients with polycythemia vera, it’s less clear for patients who are considered low risk, explained Jennifer Vaughn, MD. Patients ...
Breakthrough Therapy designation complements Rusfertide’s Orphan Drug and Fast Track designations, which together confer multiple benefits to the development program U.S. New Drug Application filing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results